Home >> Research Area >> Mifamurtide

Mifamurtide

CAS# 83461-56-7

Mifamurtide

Catalog No. BCC5241----Order now to get a substantial discount!

Product Name & Size Price Stock
Mifamurtide: 5mg $46 In Stock
Mifamurtide: 10mg Please Inquire In Stock
Mifamurtide: 20mg Please Inquire Please Inquire
Mifamurtide: 50mg Please Inquire Please Inquire
Mifamurtide: 100mg Please Inquire Please Inquire
Mifamurtide: 200mg Please Inquire Please Inquire
Mifamurtide: 500mg Please Inquire Please Inquire
Mifamurtide: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Mifamurtide

Number of papers citing our products

Chemical structure

Mifamurtide

3D structure

Chemical Properties of Mifamurtide

Cas No. 83461-56-7 SDF Download SDF
PubChem ID 55003 Appearance Powder
Formula C59H109N6O19P M.Wt 1237.5
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : ≥ 100 mg/mL (80.81 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name [3-[2-[2-[[4-[2-[2-(2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl)oxypropanoylamino]propanoylamino]-5-amino-5-oxopentanoyl]amino]propanoylamino]ethoxy-hydroxyphosphoryl]oxy-2-hexadecanoyloxypropyl] hexadecanoate
SMILES CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCNC(=O)C(C)NC(=O)CCC(C(=O)N)NC(=O)C(C)NC(=O)C(C)OC(C(C=O)NC(=O)C)C(C(CO)O)O)OC(=O)CCCCCCCCCCCCCCC
Standard InChIKey ZVLWUMPAHCEZAW-UHFFFAOYSA-N
Standard InChI InChI=1S/C59H109N6O19P/c1-7-9-11-13-15-17-19-21-23-25-27-29-31-33-52(71)80-41-47(84-53(72)34-32-30-28-26-24-22-20-18-16-14-12-10-8-2)42-82-85(78,79)81-38-37-61-57(75)43(3)62-51(70)36-35-48(56(60)74)65-58(76)44(4)63-59(77)45(5)83-55(54(73)50(69)40-67)49(39-66)64-46(6)68/h39,43-45,47-50,54-55,67,69,73H,7-38,40-42H2,1-6H3,(H2,60,74)(H,61,75)(H,62,70)(H,63,77)(H,64,68)(H,65,76)(H,78,79)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Mifamurtide Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Mifamurtide Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Mifamurtide

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 0.8081 mL 4.0404 mL 8.0808 mL 16.1616 mL 20.202 mL
5 mM 0.1616 mL 0.8081 mL 1.6162 mL 3.2323 mL 4.0404 mL
10 mM 0.0808 mL 0.404 mL 0.8081 mL 1.6162 mL 2.0202 mL
50 mM 0.0162 mL 0.0808 mL 0.1616 mL 0.3232 mL 0.404 mL
100 mM 0.0081 mL 0.0404 mL 0.0808 mL 0.1616 mL 0.202 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on Mifamurtide

Lifetime effectiveness of mifamurtide addition to chemotherapy in nonmetastatic and metastatic osteosarcoma: a Markov process model analysis.[Pubmed:25835978]

Tumour Biol. 2015 Sep;36(9):6773-9.

The mortality and progression rates in osteosarcoma differ depending on the presence of metastasis. A decision model would be useful for estimating long-term effectiveness of treatment with limited clinical trial data. The aim of this study was to explore the lifetime effectiveness of the addition of Mifamurtide to chemotherapy for patients with metastatic and nonmetastatic osteosarcoma. The target population was osteosarcoma patients with or without metastasis. A Markov process model was used, whose time horizon was lifetime with a starting age of 13 years. There were five health states: disease-free (DF), recurrence, post-recurrence disease-free, post-recurrence disease-progression, and death. Transition probabilities of the starting state, DF, were calculated from the INT-0133 clinical trials for chemotherapy with and without Mifamurtide. Quality-adjusted life-years (QALY) increased upon addition of Mifamurtide to chemotherapy by 10.5 % (10.13 and 9.17 QALY with and without Mifamurtide, respectively) and 45.2 % (7.23 and 4.98 QALY with and without Mifamurtide, respectively) relative to the lifetime effectiveness of chemotherapy in nonmetastatic and metastatic osteosarcoma, respectively. Life-years gained (LYG) increased by 10.1 % (13.10 LYG with Mifamurtide and 11.90 LYG without Mifamurtide) in nonmetastatic patients and 42.2 % (9.43 LYG with Mifamurtide and 6.63 LYG without Mifamurtide) in metastatic osteosarcoma patients. The Markov model analysis showed that chemotherapy with Mifamurtide improved the lifetime effectiveness compared to chemotherapy alone in both nonmetastatic and metastatic osteosarcoma. Relative effectiveness of the therapy was higher in metastatic than nonmetastatic osteosarcoma over lifetime. However, absolute lifetime effectiveness was higher in nonmetastatic than metastatic osteosarcoma.

Orphan drugs revisited: cost-effectiveness analysis of the addition of mifamurtide to the conventional treatment of osteosarcoma.[Pubmed:25354299]

Expert Rev Pharmacoecon Outcomes Res. 2015 Apr;15(2):331-40.

INTRODUCTION: Mepact((R)) (Mifamurtide) is the first drug approved for the treatment of high-grade resectable non-metastatic osteosarcoma in patients aged 2-30 in the last 20 years. It follows a randomized clinical trial showing a statistically-significant and clinically-relevant decrease in the risk of death without compromising safety. AIM: This study assessed the cost-effectiveness and budget impact of Mifamurtide. METHODS: The economic evaluation was done on a hypothetical cohort of young patients under the age of 30 with high-grade, non-metastatic, resectable osteosarcoma. Standard chemotherapy without Mifamurtide was used as comparator. A Markov model was adapted using Spanish costs and the results of the INT-0133 Phase III study. The analysis has been carried out from the perspective of the Spanish National Health Service, with a time horizon of up to 60 years in the base analysis. RESULTS: The observed greater efficacy of Mifamurtide in the trial translates into a gain of 3.03 (undiscounted) and 1.33 (discounted) quality-adjusted life years at an additional cost of euro102,000. The estimated budgetary impact of using Mifamurtide in 10-100% of the potential population would cost euro671,000 and euro6.7 million respectively. CONCLUSION: The cost per quality-adjusted life years gained with Mifamurtide in Spain is in the low band (

The Role of Mifamurtide in Chemotherapy-induced Osteoporosis of Children with Osteosarcoma.[Pubmed:27993113]

Curr Cancer Drug Targets. 2017;17(7):650-656.

BACKGROUND: Osteosarcoma is the most frequent malignant bone tumor in childhood and young adulthood. Long-term survivors of osteosarcoma patients show high prevalence of osteoporosis and fractures. The immunomodulatory Mifamurtide, which modulates macrophages activity, improves disease outcome. OBJECTIVE: To evaluate the role of Mifamurtide on macrophage component of bone, the osteoclasts, during chemotherapy in children with osteosarcoma. METHOD: Osteoclasts, obtained from peripheral blood cells of healthy donors were harvested in the presence or not of Mifamurtide. Moreover, osteoclast cultures were obtained from osteosarcoma patients, at onset and during chemotherapy, alone or with Mifamurtide. Pro-osteoporotic tartrateresistant acid phosphatase (TRAP), phosphokinase-beta-2 (PKCbeta2), vanilloid receptor type 1 (TRPV1), and anti-osteoporotic cannabinoid receptor type 2 (CB2) biomarkers were analyzed by bio-molecular (qPCR), biochemical (Western Blotting), and morphological (TRAP assay) approaches. RESULTS: Osteoclasts from osteosarcoma patients show significant increase of TRAP and decrease of CB2 with respect to osteoclasts from healthy donors. This osteoclast hyperactivity is more evident in osteoclasts from osteosarcoma patients during chemotherapy. Mifamurtide reduces pro-osteoporotic TRAP, PKCbeta2, TRPV1 levels and increases CB2 in osteoclasts from healthy donors. Moreover, chemotherapy-induced effects on bone resorption markers are fully reverted in osteoclasts derived from osteosarcoma patients in chemotherapy plus Mifamurtide. CONCLUSION: Our data suggest a new therapeutic role for Mifamurtide as possible anti-resorption agent in chemotherapy-induced osteoporosis in children with osteosarcoma.

Description

Mifamurtide (MTP-PE; CGP19835) is a drug against osteosarcoma.

Keywords:

Mifamurtide,83461-56-7,Natural Products, buy Mifamurtide , Mifamurtide supplier , purchase Mifamurtide , Mifamurtide cost , Mifamurtide manufacturer , order Mifamurtide , high purity Mifamurtide

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: